Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
| 1 | Acute myeloid leukemia |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 2 | Adipocytokine signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 3 | African trypanosomiasis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 4 | AGE-RAGE signaling pathway in diabetic complications |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 5 | Allograft rejection |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 6 | Alzheimer disease |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 7 | Amoebiasis |
[2] IL1R1, IL1R2 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 8 | AMPK signaling pathway |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| [1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
| D08378 | |||||
| 9 | Amyotrophic lateral sclerosis (ALS) |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 10 | Antifolate resistance |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 11 | Antigen processing and presentation |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 12 | Apelin signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 13 | Apoptosis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 14 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| 15 | Asthma |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 16 | Autophagy - animal |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 17 | Autophagy - other |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 18 | Bile secretion |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 19 | Breast cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 20 | C-type lectin receptor signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 21 | Cell adhesion molecules (CAMs) |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| 22 | Cellular senescence |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 23 | Central carbon metabolism in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 24 | Chagas disease (American trypanosomiasis) |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 25 | Choline metabolism in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 26 | Colorectal cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 27 | Cytokine-cytokine receptor interaction |
[2] ACVR2A, ACVR2B | D10620 | Bimagrumab | [1] 15 |
| [2] IL1R1, IL1R2 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 | ||
| [2] LTA, TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 28 | Dilated cardiomyopathy (DCM) |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 29 | ECM-receptor interaction |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| 30 | EGFR tyrosine kinase inhibitor resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 31 | Endocrine resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 32 | Epstein-Barr virus infection |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 33 | ErbB signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 34 | Fc epsilon RI signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 35 | Fluid shear stress and atherosclerosis |
[2] ACVR2A, ACVR2B | D10620 | Bimagrumab | [1] 15 |
| [2] IL1R1, IL1R2 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 | ||
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 36 | Focal adhesion |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| 37 | Gastric cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 38 | Glioma |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 39 | Graft-versus-host disease |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 40 | Growth hormone synthesis, secretion and action |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 41 | Hematopoietic cell lineage |
[2] IL1R1, IL1R2 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 | ||
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 42 | Hepatitis B |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 43 | Hepatitis C |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 44 | Hepatocellular carcinoma |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 45 | Herpes simplex virus 1 infection |
[2] LTA, TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| 46 | HIF-1 signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 47 | Human cytomegalovirus infection |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 48 | Human immunodeficiency virus 1 infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 49 | Human papillomavirus infection |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 50 | Human T-cell leukemia virus 1 infection |
[2] IL1R1, IL1R2 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [2] LTA, TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 51 | Huntington disease |
[1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
| D08378 | |||||
| 52 | Hypertrophic cardiomyopathy (HCM) |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 53 | IL-17 signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 54 | Inflammatory bowel disease (IBD) |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 55 | Inflammatory mediator regulation of TRP channels |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| 56 | Influenza A |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 57 | Insulin resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 58 | Insulin secretion |
[1] SNAP25 | D00783 | Botulinum toxin type A | [13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
| 59 | Insulin signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 60 | Intestinal immune network for IgA production |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| 61 | JAK-STAT signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 62 | Kaposi sarcoma-associated herpesvirus infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 63 | Legionellosis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 64 | Leishmaniasis |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 65 | Leukocyte transendothelial migration |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| 66 | Longevity regulating pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
| D08378 | |||||
| 67 | Longevity regulating pathway - multiple species |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 68 | Malaria |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 69 | MAPK signaling pathway |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 70 | Metabolic pathways |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 71 | MicroRNAs in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 72 | mTOR signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 73 | Natural killer cell mediated cytotoxicity |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 74 | Necroptosis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 75 | NF-kappa B signaling pathway |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [2] LTA, TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 76 | NOD-like receptor signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 77 | Non-alcoholic fatty liver disease (NAFLD) |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 78 | Osteoclast differentiation |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
| D08378 | |||||
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 79 | Pancreatic cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 80 | Pathogenic Escherichia coli infection |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 81 | Pathways in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
| D08378 | |||||
| 82 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 83 | Pertussis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 84 | Phospholipase D signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 85 | PI3K-Akt signaling pathway |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| 86 | PPAR signaling pathway |
[1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
| D08378 | |||||
| 87 | Prostate cancer |
[1] IL1R2 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| 88 | Proteoglycans in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 89 | Regulation of actin cytoskeleton |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| 90 | Rheumatoid arthritis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 91 | RIG-I-like receptor signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 92 | Shigellosis |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 93 | Signaling pathways regulating pluripotency of stem cells |
[2] ACVR2A, ACVR2B | D10620 | Bimagrumab | [1] 15 |
| 94 | Sphingolipid signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 95 | Synaptic vesicle cycle |
[1] SNAP25 | D00783 | Botulinum toxin type A | [13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
| 96 | Systemic lupus erythematosus |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 97 | T cell receptor signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 98 | Terpenoid backbone biosynthesis |
[1] HMGCR | D00434 | Simvastatin | [19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 99 | TGF-beta signaling pathway |
[2] ACVR2A, ACVR2B | D10620 | Bimagrumab | [1] 15 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 100 | Th17 cell differentiation |
[1] IL1R1 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
| 101 | Thermogenesis |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
| D08378 | |||||
| 102 | Thyroid cancer |
[1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
| D08378 | |||||
| 103 | Thyroid hormone signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| 104 | TNF signaling pathway |
[2] LTA, TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 105 | Toll-like receptor signaling pathway |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 106 | Toxoplasmosis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 107 | Transcriptional misregulation in cancer |
[1] IL1R2 | D02934 | Anakinra | [17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| [1] PPARG | D00945 | Pioglitazone | [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
| D08378 | |||||
| 108 | Tuberculosis |
[1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 109 | Type I diabetes mellitus |
[2] LTA, TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 110 | Type II diabetes mellitus |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
| 111 | Viral protein interaction with cytokine and cytokine receptor |
[2] LTA, TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 112 | Yersinia infection |
[1] ITGA4 | D06886 | Natalizumab | [6] 13, 15, 25, 46, 63, 96 |
| [1] TNF | D00742 | Etanercept | [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |